GERON CORP Debt Securities, Available-for-sale, Noncurrent
GERON CORP (GERN) had Debt Securities, Available-for-sale, Noncurrent of $94.52 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2025-02-27
- 2024-12-31: Debt Securities, Available-for-sale, Noncurrent $94.52M.
- 2024-09-30: Debt Securities, Available-for-sale, Noncurrent $37.31M.
- 2024-06-30: Debt Securities, Available-for-sale, Noncurrent $66.50M.
- 2024-03-31: Debt Securities, Available-for-sale, Noncurrent $20.78M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2024-12-31 | $94.52M 10-K · filed 2025-02-27 |
| 2024-09-30 | $37.31M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $66.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $20.78M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $43.30M 10-K · filed 2025-02-27 |
| 2023-09-30 | $67.82M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $28.28M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $28.10M 10-Q · filed 2023-05-11 |
| 2022-03-31 | $10.95M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $28.65M 10-K · filed 2023-03-16 |
| 2021-09-30 | $39.36M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $40.52M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $33.29M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $63.39M 10-K · filed 2022-03-10 |
| 2020-09-30 | $45.77M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $46.22M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.03M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $19.65M 10-K · filed 2021-03-11 |
| 2019-09-30 | $20.40M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $9.50M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $17.87M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $18.58M 10-K · filed 2020-03-12 |
| 2018-09-30 | $18.14M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $14.24M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |